It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look ...

Just seven weeks after projecting an 18% revenue boost for this year, Indivior has slashed its estimate to an 8% increase, ...

The two companies’ applications for China-approved PD-1 inhibitor camrelizumab and the VEGFR tyrosine kinase inhibitor ...

Editor's note: This story was corrected to note that Brooks will be Eli Lilly's interim CFO. A little more than a month after ...

Bayer’s massive reorganization championed by CEO Bill Anderson is bringing major changes to the German company’s pharma ...

While much of the attention on Novo Nordisk these days revolves around the company’s wildly popular GLP-1 drugs Ozempic and ...